Reviews in Endocrine & Metabolic Disorders

Reviews in Endocrine and Metabolic Disorders is a peer-reviewed review journal published by Springer since 2000 under the ISSN 1389-9155 and eISSN 1573-2606, covering endocrinology and metabolism with a 2025 Journal Impact Factor of 8.7 and a first quartile rank of 14 of 198 in endocrinology and metabolism《内分泌与代谢疾病综述》（Reviews in Endocrine and Metabolic Disorders）是施普林格（Springer）自 2000 年起出版的同行评审综述期刊，刊号 1389-9155、电子刊号 1573-2606，覆盖内分泌与代谢领域，2025 年影响因子为 8.7，在内分泌与代谢类 198 种期刊中列第 14 位、居第一四分位。

Scope

• The journal publishes authoritative reviews on endocrine and metabolic disorders, covering basic mechanisms, clinical manifestations, diagnosis and treatment of diseases of the endocrine system and of metabolic derangements该刊刊载内分泌与代谢疾病领域的权威综述，覆盖内分泌系统疾病与代谢紊乱的基础机制、临床表现、诊断与治疗。
• It addresses diabetes and obesity, thyroid disorders, adrenal and pituitary disease, bone and calcium metabolism, reproductive endocrinology, and inherited metabolic disorders, and it welcomes reviews that integrate basic and clinical perspectives该刊探讨糖尿病与肥胖、甲状腺疾病、肾上腺与垂体疾病、骨与钙代谢、生殖内分泌与遗传性代谢疾病，并欢迎整合基础与临床视角的综述。
• The journal publishes thematic issues on emerging topics, and article types include comprehensive reviews, mini-reviews, systematic reviews and opinion pieces that synthesise current knowledge for clinicians and researchers该刊就新兴议题出版专题，文章类型包括全面综述、小型综述、系统综述与观点文章，为临床医师与研究者综合当前知识。
• It operates single-blind peer review and follows the Springer editorial policies on research integrity, data availability and competing interests, with author guidelines published on the journal website该刊实行单盲同行评审，遵循施普林格关于研究诚信、数据可获取性与利益冲突的编辑政策，作者指南在期刊网站公布。
• The journal is a subscription title that additionally offers an article publishing charge based open access option, and it is abstracted and indexed in Science Citation Index Expanded, Scopus, PubMed and MEDLINE该刊采用订阅制并另行提供需缴纳文章处理费的开放获取选项，被（SCIE）、（Scopus）、（PubMed）与（MEDLINE）收录。
• In the 2025 Journal Citation Reports it ranks 14 of 198 titles in endocrinology and metabolism with a 93.2 percentile and its five year indicator remains in the first quartile在 2025 年版期刊引证报告中，该刊在内分泌与代谢类 198 种期刊中列第 14 位、百分位 93.2，五年指标同样位于第一四分位。

History

• The journal was launched in 2000 by Springer to provide a review venue for endocrine and metabolic disorders, and the first volume appeared in that year该刊于 2000 年由施普林格创办，旨在为内分泌与代谢疾病提供综述平台，第一卷同年出版。
• It was established to complement the primary research journals in endocrinology with a dedicated review title, and it has retained the review focus throughout its history该刊设立的目的是以内分泌学原创研究期刊的专门综述刊为补充，自创办起一直保持综述定位。
• The Journal Impact Factor moved from 6.514 in 2021 to 9.306 in 2022, to 8.0 in 2024 and to 8.7 in 2025, maintaining first quartile standing in endocrinology and metabolism throughout该刊影响因子由 2021 年的 6.514 升至 2022 年的 9.306，再降至 2024 年的 8.0 与 2025 年的 8.7，始终居内分泌与代谢类第一四分位。
• The journal has progressively expanded its coverage to address obesity, metabolic syndrome and the endocrine dimensions of non-communicable diseases, reflecting the broadening of the field该刊逐步扩展学科范围以涵盖肥胖、代谢综合征与非传染性疾病的内分泌维度，反映该领域的拓展。
• The publisher carries the journal on Springer Link and the digital object identifier prefix of its articles is 10.1007, shared with other Springer journals出版方将该刊载于施普林格链接平台，其文章的数字对象唯一标识符前缀为（10.1007），与施普林格其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an international editorial board whose members are drawn from endocrinology, diabetes and metabolism divisions of universities and research institutes across the world该刊由一位主编带领，配以由世界各地大学与研究机构内分泌、糖尿病与代谢科室学者组成的国际编委会。
• The editorial team includes associate editors responsible for subject areas such as diabetes, thyroid and adrenal disorders, bone metabolism, reproductive endocrinology and inherited metabolic disease, reflecting the breadth of the journal编辑团队设有副编辑，分别负责糖尿病、甲状腺与肾上腺疾病、骨代谢、生殖内分泌与遗传性代谢疾病等方向，对应刊物的广度。
• Editorial handling follows the Springer editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托施普林格的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the Springer standards on reviewer recruitment, conflict of interest management and editorial independence同行评审采用单盲方式，该刊遵循施普林格在审稿人遴选、利益冲突管理与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at Springer Link and updated as new members join or existing members step down编委名单在施普林格链接期刊页公布，并随成员增减而更新。